サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1316918

がんモノクローナル抗体市場：タイプ別（キメラ、ヒト、ヒト化）、用途別（血液がん、乳がん、大腸がん）、エンドユーザー別-2023-2030年の世界予測

Cancer Monoclonal Antibodies Market by Type (Chimeric, Human, Humanized), Application (Blood Cancer, Breast Cancer, Colorectal Cancer), End-user - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
がんモノクローナル抗体市場：タイプ別（キメラ、ヒト、ヒト化）、用途別（血液がん、乳がん、大腸がん）、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がんモノクローナル抗体の世界市場は、2023年にCAGR 12.82%で698億7,000万米ドルと予測され、2030年には驚異的な1,632億8,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のがんモノクローナル抗体市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.がんモノクローナル抗体の世界市場規模および予測は？

2.予測期間中、世界のがんモノクローナル抗体市場を形成するCOVID-19の阻害要因と影響は？

3.がんモノクローナル抗体の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.がんモノクローナル抗体の世界市場における競争戦略は？

5.がんモノクローナル抗体の世界市場における技術動向と規制の枠組みは？

6.がんモノクローナル抗体の世界市場における主要ベンダーの市場シェアは？

7.がんモノクローナル抗体の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中でさまざまながんの罹患率が上昇
      • 免疫反応を改善および抑制するためのがんモノクローナル抗体の意識の高まり
      • 堅牢なパイプラインとともに医薬品の承認を増加
    • 抑制要因
      • 特定の分野における認識の欠如
    • 機会
      • 新たに開発されたモノクローナル抗体の臨床試験の増加
      • がんモノクローナル抗体の開発における共同アプローチ
    • 課題
      • がんモノクローナル抗体の使用に伴う悪影響
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 がんモノクローナル抗体市場：タイプ別

  • キメラ
  • 人間
  • 人間化された
  • ネズミ

第7章 がんモノクローナル抗体市場：用途別

  • 血液がん
  • 乳がん
  • 結腸直腸がん
  • 肝臓がん
  • 肺がん
  • 黒色腫

第8章 がんモノクローナル抗体市場：エンドユーザー別

  • 病院
  • 調査機関
  • 調査

第9章 南北アメリカのがんモノクローナル抗体市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のがんモノクローナル抗体市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのがんモノクローナル抗体市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CANCER MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2022 VS 2030
  • FIGURE 3. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS
  • FIGURE 9. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. CANCER MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. CANCER MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 148. CANCER MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 149. CANCER MONOCLONAL ANTIBODIES MARKET LICENSE & PRICING
目次
Product Code: MRR-450A0628C5C9

The Global Cancer Monoclonal Antibodies Market is forecasted to grow significantly, with a projected USD 69.87 billion in 2023 at a CAGR of 12.82% and expected to reach a staggering USD 163.28 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Monoclonal Antibodies Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Monoclonal Antibodies Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Chimeric, Human, Humanized, and Murine. The Humanized is projected to witness significant market share during forecast period.

Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, and Melanoma. The Melanoma is projected to witness significant market share during forecast period.

Based on End-user, market is studied across Hospitals, Research Institutes, and Research Laboratories. The Research Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Monoclonal Antibodies Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Monoclonal Antibodies Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Monoclonal Antibodies Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Monoclonal Antibodies Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Monoclonal Antibodies Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Monoclonal Antibodies Market?

6. What is the market share of the leading vendors in the Global Cancer Monoclonal Antibodies Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Monoclonal Antibodies Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Monoclonal Antibodies Market, by Type, 2022 vs 2030
  • 4.3. Cancer Monoclonal Antibodies Market, by Application, 2022 vs 2030
  • 4.4. Cancer Monoclonal Antibodies Market, by End-user, 2022 vs 2030
  • 4.5. Cancer Monoclonal Antibodies Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of different cancers worldwide
      • 5.1.1.2. Growing awareness of cancer monoclonal antibodies to improve & suppress the immune responses
      • 5.1.1.3. Increasing drug approvals along with a robust pipeline
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness in certain areas
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing clinical trials of newly developed monoclonal antibodies
      • 5.1.3.2. Collaborative approach for development of cancer monoclonal antibodies
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with use of cancer monoclonal antibodies
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Cancer Monoclonal Antibodies Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric
  • 6.3. Human
  • 6.4. Humanized
  • 6.5. Murine

7. Cancer Monoclonal Antibodies Market, by Application

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Liver Cancer
  • 7.6. Lung Cancer
  • 7.7. Melanoma

8. Cancer Monoclonal Antibodies Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Research Laboratories

9. Americas Cancer Monoclonal Antibodies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Monoclonal Antibodies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Monoclonal Antibodies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing